Medexus Announces Changes to Senior Management
October 15 2019 - 11:43AM
Medexus Pharmaceuticals Inc. (the “
Company”)
(TSXV: MDP, OTCQB: PDDPF) today announced changes to the Company’s
senior management team. Effective immediately, Mr. Sylvain Chrétien
will no longer serve as the Company’s President, Canadian
Operations. In accordance with his employment agreement, Mr.
Chrétien is also required to resign from the Board of Directors of
the Company. Also effective immediately, Mr. Benoît Hébert will be
departing from his role as the Company’s Vice President, Business
Development & Licensing.
Ken d’Entremont, Chief Executive Officer of the
Company, commented: “On behalf of the Board of Directors and
management team, we would like to thank Mr. Chrétien and Mr. Hébert
for their invaluable work, contributions and stewardship over the
years and we wish them both much success in their future
endeavours. Mr. Chrétien founded Pediapharm Inc., our predecessor
entity, and loyally served as President and Chief Executive Officer
of Pediapharm Inc. from 2008 until 2018. We are very grateful for
his many years of guidance and leadership.”
About Medexus Pharmaceuticals
Inc.
Medexus is a leading specialty pharmaceutical
company with a strong North American commercial platform. The
Company’s vision is to provide the best healthcare products to
healthcare professionals and patients, through our core values of
Quality, Innovation, Customer Service and Teamwork. Medexus is
focused on the therapeutic areas of auto-immune disease and
pediatrics. The leading products are Rasuvo™ and Metoject®, a
unique formulation of methotrexate (auto-pen and pre-filled
syringe) designed to treat rheumatoid arthritis and other
auto-immune diseases; and Rupall™, an innovative allergy medication
with a unique mode of action.
For further information, please
contact:Ken d’Entremont, Chief Executive OfficerMedexus
Pharmaceuticals Inc.Tel: 905-676-0003E-mail:
ken.dentremont@medexus.com
Roland Boivin, Chief Financial OfficerMedexus
Pharmaceuticals Inc.Tel: 514-762-2626 ext. 202E-mail:
roland.boivin@medexus.com
Investor Relations
(U.S.):Crescendo Communications, LLCTel:
+1-212-671-1020E-mail: mdp@crescendo-ir.com
Investor Relations
(Canada):Frank CandidoDirect Financial Strategies and
Communication Inc.Tel: 514-969-5530E-mail:
frank.candido@medexus.com
Neither the TSX Venture Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the TSX Venture Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Jul 2024 to Aug 2024
Medexus Pharmaceuticals (TSXV:MDP)
Historical Stock Chart
From Aug 2023 to Aug 2024